Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

severe hypertriglyceridemia

Novartis building

FDA panel rejects Novartis’ heart failure hope serelaxin

Decision follows EMA knock back earlier this year

- PMLiVE

AstraZeneca launches delivery service for Nexium

Expands its US direct-to-patient programme

Novartis building

More bad news for Novartis on heart failure candidate

FDA reviewers recommend against approving serelaxin

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

Pfizer’s meningitis vaccine ‘a breakthrough’

FDA to speed up review process for bivalent rLP2086

- PMLiVE

Celgene gets FDA OK for first oral psoriatic arthritis drug

Otezla wins US approval to treat the auto-immune disease

AstraZeneca to develop mHealth cardiovascular services

Willwork with Vodafone in a new global partnership

- PMLiVE

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

- PMLiVE

Alderley Park ‘will remain flagship bioscience location’

Manchester Science Parks takes over former AstraZeneca site

- PMLiVE

FDA approves migraine headband

STX-Med’s electronic Cefaly device offers drug-free treatment option

- PMLiVE

AZ launches combination diabetes drug in UK

Xigduo combines Forxiga and metformin

- PMLiVE

FDA scrutiny of alirocumab hits Regeneron and Sanofi

Regulator to assess neurocognitive effects of cholesterol drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links